| Filing date | Form | Description | Filing Group | View |
|---|---|---|---|---|
| 424B3 | Form of prospectus reflecting facts events constituting substantive change from last form |
Registration Statements
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| 4 | Statement of changes in beneficial ownership of securities |
3,4,5
|
||
| 3 | Initial filing by director officer or owner of more than ten percent |
3,4,5
|
||
| EFFECT | EFFECT |
Other
|
||
| 10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | |
| S-3/A | Pre-effective amendment to an S-3 filing |
Registration Statements
|
||
| CORRESP | CORRESP |
Other
|
||
| 8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
| S-3/A | Pre-effective amendment to an S-3 filing |
Registration Statements
|
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.
